Sandra Boom - Concepedia

Author

Sandra Boom

Johnson & Johnson (United States)

Also Known As

Boom, S.P.A., S BOOM, S Boom, S P Boom, S. Boom, S.P.A. Boom, Sandra Boom, Sandra P A Boom, Sandra P.A. Boom

Publications

607

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)Radboud University Nijmegen Janssen (Belgium)Janssen (Germany)Karolinska Institutet

About

Sandra Boom is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	182
2	Health Sciences	2	2	30
3	Social Sciences	2	2	56
4	Education	1	1	10
5	Endocrinology	1	1	12

Sandra Boom

Publications

594

Citations

H-Index

Page 1

	Year	Citations
Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans Marc Vermeir, Ineke Naessens, Bart Remmerie, Drug Metabolism and Disposition	2008	158
Validated LC–MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine Marc De Meulder, Bart Remmerie, Ronald P. de Vries, Journal of Chromatography B Therapeutic Drug MonitoringUrologyMedicineLc–ms/ms MethodsBioanalysis	2008	69
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia Joris Berwaerts, Adriaan Cleton, Stefaan Rossenu, Journal of Psychopharmacology	2009	48
Single‐ and Multiple‐Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release Sandra Boom, Krishna Talluri, Luc Janssens, The Journal of Clinical Pharmacology	2009	38
Organic cation transport and cationic drug interactions in freshly isolated proximal tubular cells of the rat. Sandra Boom, F. W. J. Gribnau, Frans G. M. Rüssel Journal of Pharmacology and Experimental Therapeutics	1992	37
PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies Per Karlsson, E Dencker, Sigrid Nyberg, Clinical Pharmacology & Therapeutics Healthy SubjectsPsychopharmacologyPharmacotherapySingle-dose StudiesSocial Sciences	2006	37
The influence of hepatic impairment on the pharmacokinetics of paliperidone Sandra Boom, An Thyssen, Herta Crauwels, International Journal of Clinical Pharmacology and Therapeutics	2009	36
No pharmacokinetic interaction between paliperidone extended‐release tablets and trimethoprim in healthy subjects An Thyssen, Adriaan Cleton, Krishna Talluri, Human Psychopharmacology Clinical and Experimental	2009	30
PII-72A pharmacokinetic model to document the interconversion between Paliperidone’s enantiomers Adriaan Cleton, Stefaan Rossenu, An Vermeulen, Clinical Pharmacology & Therapeutics	2006	21
Pharmacokinetics and dopamine d2 and serotonin 5-ht2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115) Per Karlsson, L. Hargarter, E Dencker, Pharmacopsychiatry Molecular PharmacologyHealthy SubjectsAddictionMedicinePsychotropic Medication	2007	19

Page 1